Corticosteroid shown to be safe for long-term SAC control

May 1, 2003

Clinical professor of ophthalmology, University of South Florida College of Medicine, Tampa.

Chet Scerra

Tampa, FL-Loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb Pharmaceuticals and Pharmos Corp.), the first corticosteroid specifically designed for signs and symptoms of seasonal allergic conjunctivitis (SAC), is safe for long-term use, according to a recent multicenter study.